CONBRIZA

This brand name is authorized in Austria, Croatia, Cyprus, Estonia, Ireland, Lithuania, Netherlands, Poland, Spain.

Active ingredients

The drug CONBRIZA contains one active pharmaceutical ingredient (API):

1
UNII J70472UD3D - BAZEDOXIFENE ACETATE
 
Read more about Bazedoxifene

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 CONBRIZA Film-coated tablet MPI, EU: SmPC European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
G03XC02 Bazedoxifene G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03X Other sex hormones and modulators of the genital system → G03XC Selective estrogen receptor modulators
Discover more medicines within G03XC02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
EE Ravimiamet 1413863, 1413874, 1413885, 1413896, 1523696
ES Centro de información online de medicamentos de la AEMPS 09511001
IE Health Products Regulatory Authority 18010
LT Valstybinė vaistų kontrolės tarnyba 1037192, 1037193, 1037194, 1037195, 1063650
NL Z-Index G-Standaard, PRK 90638
PL Rejestru Produktów Leczniczych 100218813

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈